Antibodies against human csf-1r and uses thereof

Abstract

The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

1 . An antibody binding to human CSF-1R, characterized in binding to same epitope as the deposited antibody DSM ACC2922. 
     
     
         2 . The antibody according to  claim 1  characterized in comprising as heavy chain variable domain CDR3 region a CDR3 region of SEQ ID NO: 1, SEQ ID NO: 9, or SEQ ID NO: 17. 
     
     
         3 . The antibody according to  claim 2 , characterized in that
 a) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6, or   b) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and the light chain variable domain comprises a CDR3 region of SEQ ID NO:12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14; or   c) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18, and a CDR1 region of SEQ ID NO: 19, and i the light chain variable domain comprises a CDR3 region of SEQ ID NO:20, a CDR2 region of SEQ ID NO: 21, and a CDR1 region of SEQ ID NO: 22; or   d) a CDR grafted, humanized or T cell epitope depleted antibody variant of the antibodies of a), b) or c).   
     
     
         4 . The antibody according to  claim 3 , characterized in comprising
 a) the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 7, and the amino acid sequence of the light chain variable domain is SEQ ID NO:8, or   b) the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 15, and the amino acid sequence of the light chain variable domain is SEQ ID NO:16, or   c) the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 23, and the amino acid sequence of the light chain variable domain is SEQ ID NO:24; or   d) a CDR grafted, humanized or T cell epitope depleted antibody variant of the antibodies of a), b) or c).   
     
     
         5 . The antibody according to  claims 1  to  4 , characterized in that said antibody is of human IgG4 subclass or is of human IgG1 subclass, 
     
     
         6 . Pharmaceutical composition characterized in comprising an antibody or fragment according to  claims 1  to  5 . 
     
     
         7 . The antibody according to  claims 1  to  5  for the treatment of cancer. 
     
     
         8 . The antibody according to  claims 1  to  5  for the treatment of bone loss. 
     
     
         9 . The antibody according to  claims 1  to  5  for the prevention or treatment of metastasis. 
     
     
         10 . The antibody according to  claims 1  to  5  for the treatment of inflammatory diseases. 
     
     
         11 . Nucleic acid encoding a heavy chain of an antibody binding to CSF-1R, characterized in that said antibody comprises a variable domain according to  claim 2 ,  3  or  34 . 
     
     
         12 . Expression vectors characterized in comprising a nucleic acid according to  claim 11  for the expression of an antibody binding to CSF-1R in a prokaryotic or eukaryotic host cell. 
     
     
         13 . Prokaryotic or eukaryotic host cell comprising a vector according to  claim 12 . 
     
     
         14 . Method for the production of a recombinant antibody according to  claims 1  to  5 , characterized by expressing a nucleic acid according to  claim 11  in a prokaryotic or eukaryotic host cell and recovering said antibody from said cell or the cell culture supernatant. 
     
     
         15 . An antibody binding to human CSF-1R, characterized in that
 a) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO:3, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6, or   b) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and the light chain variable domain comprises a CDR3 region of SEQ ID NO:12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14; or   c) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18, and a CDR1 region of SEQ ID NO: 19, and i the light chain variable domain comprises a CDR3 region of SEQ ID NO:20, a CDR2 region of SEQ ID NO: 21, and a CDR1 region of SEQ ID NO: 22; or   d) a CDR grafted, humanized or T cell epitope depleted antibody variant of the antibodies of a), b) or c).   
     
     
         16 . The antibody according to  claim 15 , characterized in comprising
 a) the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 7, and the amino acid sequence of the light chain variable domain is SEQ ID NO:8, or   b) the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 15, and the amino acid sequence of the light chain variable domain is SEQ ID NO:16, or   c) the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 23, and the amino acid sequence of the light chain variable domain is SEQ ID NO:24; or   d) a CDR grafted, humanized or T cell epitope depleted antibody variant of the antibodies of a), b) or c).